Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of no Inferiority Between Two Doses (0.500mg and 0.625mg) of Bevacizumab Intravitreal in the Treatment of Retinopathy of Prematurity Type 1

NCT02090322 is registered in ClinicalTrials.gov with Universidad Autonoma de San Luis Potosí as lead sponsor.

NCT NCT02090322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02090322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of no Inferiority Between Two Doses (0.500mg and 0.625mg) of Bevacizumab Intravitreal in the Treatment of Retinopathy of Prematurity Type 1
Lead sponsor
Universidad Autonoma de San Luis Potosí
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2013
Completion date
March 31, 2014
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity